Pfizer Will Monitor Off-Label Drug Use And Report To IG Under Neurontin Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
Corporate integrity agreement will be carefully studied in pharmaceutical industry given uncertainties surrounding off-label promotion rules. Pfizer agrees to establish clear policies and keep close tabs on off-label use – but the agreement does not define prohibited or permitted activities.
You may also be interested in...
Cephalon Settles Federal Investigation Of Marketing Practices For $425 Million
Cephalon enters into a corporate integrity agreement with HHS Inspector General, which likely will be in line with its existing compliance program, firm tells “The Pink Sheet” DAILY.
Cephalon Settles Federal Investigation Of Marketing Practices For $425 Million
Cephalon enters into a corporate integrity agreement with HHS Inspector General, which likely will be in line with its existing compliance program, firm tells “The Pink Sheet” DAILY.
Biotechs’ Size A Competitive Advantage Over Big Pharma In Compliance Arena – BIO Panel
Smaller biotechs should view current regulatory environment as a way to leverage size to better compete with larger companies, Cubist exec says.